21343-40-8
中文名稱(chēng)
25-羥麥角甾醇
英文名稱(chēng)
25-HYDROXYVITAMIN D2
CAS
21343-40-8
分子式
C28H44O2
MDL 編號(hào)
MFCD02683431
分子量
412.65
MOL 文件
21343-40-8.mol
更新日期
2024/12/25 08:44:54
21343-40-8 結(jié)構(gòu)式
基本信息
中文別名
25-羥麥角甾醇25-羥基維生素 D2
英文別名
25-hydroxyvitamind25-hydroxycalciferol
(E,3S,6S)-6-[(1R,3aR,4E,7aS)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidene-cyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2,3-dimethyl-hept-4-en-2-ol
25-hydoxyergocalciferol
3-{2-[1-(5-Hydroxy-1,4,5-trimethyl-hex-2-enyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol ( 25-Hydroxyvitamin D2 )
25-Hydroxycalciferol, 25-Hydroxyergocalciferol
(5Z,7E,22E)-25-Hydroxy-9,10-secoergosta-5,7,10(19),22-tetren-3β-ol
(5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetrene-3β,25-diol
Ercalcidiol
所屬類(lèi)別
分析化學(xué)：標(biāo)準(zhǔn)物質(zhì)物理化學(xué)性質(zhì)
熔點(diǎn)45-51°C
沸點(diǎn)542.3±38.0 °C(Predicted)
密度1.02±0.1 g/cm3(Predicted)
閃點(diǎn)14℃
儲(chǔ)存條件−20°C
溶解度Limited solubility, soluble in DMSO or ethanol
酸度系數(shù)(pKa)14.74±0.20(Predicted)
形態(tài)白色結(jié)晶性粉末。
顏色White to off-white
BRN4716773
穩(wěn)定性對(duì)光敏感、對(duì)溫度敏感
CAS 數(shù)據(jù)庫(kù)21343-40-8(CAS DataBase Reference)
安全數(shù)據(jù)
警示詞危險(xiǎn)
危險(xiǎn)性描述H225-H319
防范說(shuō)明P210-P305+P351+P338
危險(xiǎn)品標(biāo)志T+,F
危險(xiǎn)類(lèi)別碼24/25-26-48/25-11
安全說(shuō)明28-36/37-45-16-7
危險(xiǎn)品運(yùn)輸編號(hào)UN2811 6.1/PG 2
WGK Germany3
常見(jiàn)問(wèn)題列表
生物活性
Ercalcidiol 是一種 vitamin D2 代謝物，作為 vitamin D 營(yíng)養(yǎng)狀態(tài)的指標(biāo)。靶點(diǎn)
|
Human Endogenous Metabolite
|
體外研究
Differentiation between Ercalcidiol (25(OH)D 2 ) and 25(OH)D 3 is important for monitoring vitamin D therapy, as vitamin D 2 is the predominant prescription form. The half-life of Ercalcidiol is shorter than that of 25(OH)D 3 and it binds less well to the vitamin D binding protein, making it less potent and, therefore, required to be administered at much higher doses than vitamin D 3 . Some currently used assays have a diminished capacity to detect Ercalcidiol, which can lead to dangerous overdosing when attempting to monitor therapy with vitamin D 2 .